Observational study refines relapse risk after blinatumomab in childhood leukemia

The amount of leukemia remaining after the first cycle of blinatumomab was the strongest predictor of subsequent relapse in an observational study of more than 200 children and young people with B-cell acute lymphoblastic leukemia treated across 24 centers in the United Kingdom and Ireland. Researchers from Newcastle University and Great Ormond Street Hospital also found that two genetic subtypes, IKZF1plus and DUX4-rearranged leukemia, were associated with poorer treatment responses and a higher risk of relapse. Together, early response and genetic information proved more informative for relapse-risk assessment than many of the traditional factors used in patients receiving chemotherapy.

Published in Blood Advances on September 1, 2026, the cohort study examined children and young people receiving frontline blinatumomab as a replacement for parts of standard chemotherapy. The investigators described it as the first comprehensive analysis of relapse-risk factors in this immunotherapy-based setting. Risk classifications for childhood acute lymphoblastic leukemia have traditionally incorporated age, white blood cell count, high-risk genetic features and the presence of measurable residual disease before treatment.

In this cohort, however, many of those chemotherapy-derived indicators were no longer reliable predictors of relapse among patients receiving blinatumomab. The team collected treatment-response data through regional laboratories, while genetic testing—including whole genome sequencing—was performed through NHS Genomics Laboratory Hubs before central analysis. The level of leukemia remaining after the first cycle of blinatumomab emerged as the strongest individual predictor of future relapse.

The investigators separately identified IKZF1plus and DUX4-rearranged leukemia as genetic subtypes associated with a poorer response to treatment and elevated relapse risk. The observational design establishes associations within the studied group rather than proving that risk-guided treatment decisions improve survival or reduce toxicity. Based on the results, the researchers developed a risk-stratification tool called BlinPredict.

It combines the early treatment response with genetic information to identify patients at increased risk of cancer returning. Professor Anthony Moorman, a joint lead author from Newcastle University, said the study calls into question whether decades-old risk factors derived from chemotherapy-based treatment remain applicable during the blinatumomab era. Dr Sujith Samarasinghe, Consultant Paediatric Haematologist at Great Ormond Street Hospital and the other joint lead author, said more accurate relapse-risk assessment could help clinicians identify patients likely to have exceptional outcomes with reduced chemotherapy and those who may need another treatment approach.

The findings have already informed revisions to national UK treatment guidelines, according to the Newcastle University release, which was issued on October 21, 2026. That implementation does not mean the observational study itself tested whether BlinPredict-guided treatment improves clinical outcomes; rather, it shows that the research has begun influencing how treatment is classified and delivered. The study was supported by Horizon Europe, the Marie Skłodowska-Curie Action and Cancer Research UK.

Future work will examine why some leukemias resist blinatumomab and whether relevant risk factors also apply to other populations, including adults with acute lymphoblastic leukemia. For now, the central result is a more individualized framework for estimating relapse risk after frontline blinatumomab, based on the amount of disease remaining after the first treatment cycle and the leukemia’s genetic features.

Subject of Research: Relapse-risk stratification after frontline blinatumomab in childhood B-cell acute lymphoblastic leukemia

Article Title: Breakthrough study advances personalized medicine in childhood leukemia

Article References: Breakthrough study advances personalized medicine in childhood leukemia. Original publication (Bibliographic details unavailable.)

Image Credits: AI Generated

DOI: Not provided

Keywords: acute lymphoblastic leukemia, blinatumomab, pediatric cancer, relapse risk, treatment response, cancer genetics, risk stratification, BlinPredict, immunotherapy, whole genome sequencing, Breakthrough, advances